The stock of Molecular Templates Inc (MTEM) has seen a -73.75% decrease in the past week, with a -68.23% drop in the past month, and a -72.80% decrease in the past quarter. The volatility ratio for the week is 2.96%, and the volatility levels for the past 30 days are at 6.86% for MTEM. The simple moving average for the last 20 days is -71.62% for MTEM stock, with a simple moving average of -81.50% for the last 200 days.
Is It Worth Investing in Molecular Templates Inc (NASDAQ: MTEM) Right Now?
The 36-month beta value for MTEM is also noteworthy at 1.13. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MTEM is 5.44M, and at present, short sellers hold a 2.61% of that float. The average trading volume of MTEM on October 14, 2024 was 61.47K shares.
MTEM) stock’s latest price update
The stock price of Molecular Templates Inc (NASDAQ: MTEM) has plunged by -74.28 when compared to previous closing price of 1.47, but the company has seen a -73.75% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-14 that AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the second quarter of 2024.
Analysts’ Opinion of MTEM
Many brokerage firms have already submitted their reports for MTEM stocks, with BofA Securities repeating the rating for MTEM by listing it as a “Buy.” The predicted price for MTEM in the upcoming period, according to BofA Securities is $12 based on the research report published on April 21, 2021 of the previous year 2021.
UBS, on the other hand, stated in their research note that they expect to see MTEM reach a price target of $13. The rating they have provided for MTEM stocks is “Neutral” according to the report published on February 01st, 2021.
Jefferies gave a rating of “Buy” to MTEM, setting the target price at $21 in the report published on September 08th of the previous year.
MTEM Trading at -72.79% from the 50-Day Moving Average
After a stumble in the market that brought MTEM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.48% of loss for the given period.
Volatility was left at 6.86%, however, over the last 30 days, the volatility rate increased by 2.96%, as shares sank -75.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -77.14% lower at present.
During the last 5 trading sessions, MTEM fell by -77.78%, which changed the moving average for the period of 200-days by -91.44% in comparison to the 20-day moving average, which settled at $1.3293. In addition, Molecular Templates Inc saw -89.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MTEM starting from BIOTECH TARGET N V, who purchase 250,000 shares at the price of $2.35 back on Apr 02 ’24. After this action, BIOTECH TARGET N V now owns 1,279,820 shares of Molecular Templates Inc, valued at $587,500 using the latest closing price.
Stock Fundamentals for MTEM
Current profitability levels for the company are sitting at:
- -0.34 for the present operating margin
- 0.8 for the gross margin
The net margin for Molecular Templates Inc stands at -0.29. The total capital return value is set at -0.45. Equity return is now at value -929.14, with -50.24 for asset returns.
Based on Molecular Templates Inc (MTEM), the company’s capital structure generated 0.61 points at debt to capital in total, while cash flow to debt ratio is standing at -2.17. The debt to equity ratio resting at 1.55. The interest coverage ratio of the stock is -111.43.
Currently, EBITDA for the company is -3.56 million with net debt to EBITDA at -0.27. When we switch over and look at the enterprise to sales, we see a ratio of 0.15. The receivables turnover for the company is 32.04for trailing twelve months and the total asset turnover is 0.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.56.
Conclusion
In summary, Molecular Templates Inc (MTEM) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
